医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutica

2014年02月19日 PM11:25
このエントリーをはてなブックマークに追加


 

BANGALORE, India

Jubilant Biosys, a Bengaluru based subsidiary of Jubilant Life Sciences, announced today that it has expanded its drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium. The alliance was forged initially in the year 2011 and aims to deliver preclinical candidates to Janssen. The new agreement into multiple therapeutic areas has been expanded owing to Jubilant’s diversified skill sets in various therapeutic areas. Most of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Center, USA.

Janssen Pharmaceutica, Belgium is part of the ‘Janssen Pharmaceutical Companies of Johnson & Johnson.’ The collaboration between the two organizations has been expanded to leverage Jubilant’s drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas. Jubilant will carry out research services and will deliver preclinical candidates to Janssen for potential development and commercialization. In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialization.

“We are pleased to announce the expansion of the Janssen-Jubilant collaboration and look forward to discovering Novel Chemical Entities (NCEs) that address the unmet medical needs in these important disease areas,” said Dr. Subir K. Basak, President, Jubilant Biosys (Global Drug Discovery Services). “Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership.”

About Jubilant Biosys Ltd.:

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd., a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. Jubilant Biosys is a leading provider of integrated drug discovery solutions to the global pharmaceutical industry. Biosys has pioneered the risk shared collaborative discovery model and has a demonstrated track record of placing assets in the clinic via multiple partnerships in the therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS and others.

Learn more about us at www.jubilantbiosys.com, www.jubl.com

About Janssen Pharmaceutica

Janssen Pharmaceutica is a part of the worldwide Janssen Pharmaceutical Group of Johnson and Johnson. Janssen Pharmaceutica is one of the most innovative pharmaceutical companies in the world and the Janssen research and development centre develops products for a wide range of disease areas, such as mental disorders, neurological problems, infectious diseases, immunological disorders, cancer, and cardiovascular and metabolic conditions.

For more info, visit www.janssenpharmaceutica.be

CONTACT

Perfect Relations
Sudipta Das
+91 9650602489
sdas@perfectrelations.com
or
Jubilant
Life Sciences Limited
Nidhi Malik
+91‐120 436 1062
nidhi_malik@jubl.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent